9 Meters Biopharma Inc
OTC:NMTRQ
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.0001
0.0003
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
9 Meters Biopharma Inc
Research & Development
9 Meters Biopharma Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
9 Meters Biopharma Inc
OTC:NMTRQ
|
Research & Development
-$32.4m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-7%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.5B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-8%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$12.6B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
9 Meters Biopharma Inc
Glance View
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. The company is headquartered in Raleigh, North Carolina and currently employs 21 full-time employees. The company went IPO on 2016-07-08. The firm is focused on developing treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs. Its pipeline includes Vurolenatide, Larazotide, NM-102, NM-003, NM-136 and NM-004. Vurolenatide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that combines exenatide with an extended half-life technology for treatment of short bowel syndrome (SBS). Larazotide is an 8-amino acid peptide formulated into an orally administered capsule for treatment of celiac disease. NM-102 is a small molecule peptide, is being developed as a potential microbiome modulator and is undergoing an indication selection process. NM-003 is a long-acting GLP-2 receptor agonist, for prevention of acute graft versus host disease. NM-004 is a double-cleaved mesalamine with an immunomodulator for pediatric ulcerative colitis.
See Also
What is 9 Meters Biopharma Inc's Research & Development?
Research & Development
-32.4m
USD
Based on the financial report for Mar 31, 2023, 9 Meters Biopharma Inc's Research & Development amounts to -32.4m USD.
What is 9 Meters Biopharma Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-38%
Over the last year, the Research & Development growth was -19%. The average annual Research & Development growth rates for 9 Meters Biopharma Inc have been -29% over the past three years , -38% over the past five years .